CRIG's 1st industrial partnering event attracted 140 academic and industrial attendees

The first CRIG industrial partnering event (read more about the event and the program), one year after CRIG's launch was a success, bringing together 140 registrants with 45 different affiliations, of which 34 were industrial. In 26 presentations over 4 different seminars, new discoveries and opportunities in the field of cancer diagnostics, cancer therapeutics, supporting enabling technologies and research platforms and expertise were explored.

A very diverse spectrum of innovations was discussed. Several pitches focused on different stages of biomarker development, including glycoproteins, RNA, methylation in situ hybridization, extracellular vesicles and extensive theranostic solutions based on immunohistochemistry and next-generation sequencing. Other speakers evaluated the potential of novel techniques, such as as photoporation for controlled cellular delivery and lipid nanoparticles for mRNA-based immunotherapy. Also a diverse set of in vivo models, the utility of a single cell screening platform and data analysis, as well as 3D printing for biomedical applications were discussed as part of the expertise within the CRIG network. Ultimately, also new targets and therapeutic candidates were spotlighted; some of them with great potential but still needing partnership for their further development, and one compound with phase II clinical stage for AML (with an academic origin).

The event was an important incentive for academic researchers and industrial partners to meet each other, discover opportunities and start collaborations in the field of oncology. We look forward to future editions!